ClinicalTrials.Veeva

Menu

MR-based Collateral Imaging to Predict Response to Endovascular Treatment of Stroke (FAST-COLL Study)

Samsung Medical Center logo

Samsung Medical Center

Status

Unknown

Conditions

Stroke

Treatments

Procedure: Endovascular treatment

Study type

Observational

Funder types

Other

Identifiers

NCT02668627
SMC 2013-12-088

Details and patient eligibility

About

Based on the results of recent randomized controlled trials, current international guidelines recommend the initiation of endovascular treatment within 6 hours of symptom onset for acute ischemic stroke. Endovascular treatment may be beneficial in selected patients beyond 6 hour time window. In particular, treatment response to endovascular therapy may be greatly influenced by pretreatment collateral status. The aim of this study is to evaluate whether MRI-based collateral imaging (the Fast Analysis SysTem for COLLaterals, 'FAST-COLL') is feasible and can predict the response to endovascular treatment in a wide range of patients with acute ischemic stroke .

Enrollment

120 estimated patients

Sex

All

Ages

20+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Acute ischemic stroke
  • Age 20 years and older
  • Disabling stroke defined as a baseline NIHSS > 5 at the time of arrival
  • Onset (last-seen-well) time to endovascular treatment time < 12 hours
  • Confirmed symptomatic intracranial occlusion, based on CT or MR angiography, at one or more of the following locations: Carotid T/L, M1 MCA, or M1-MCA equivalent (2 or more M2-MCAs)
  • Signed informed consent or appropriate signed deferral of consent where approved

Exclusion criteria

  • Baseline non-contrast CT reveals a moderate/large core defined as extensive early ischemic changes of ASPECTS 0-5 in the territory of symptomatic intracranial occlusion.
  • Clinical history, past imaging or clinical judgment suggests that the intracranial occlusion is chronic
  • Unable to undergo MRI (contraindicated or poor cooperation)
  • Patient has a severe or fatal comorbid illness that will prevent improvement or follow-up or that will render the procedure unlikely to benefit the patient
  • Pregnant females as determined by positive urine hCG test or lactating females

Trial contacts and locations

1

Loading...

Central trial contact

Jong-Won Chung, MD; Yun Jeong Lim, RN

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems